Madopar® 250

DRUG2 trials

Sponsors

Bial - Portela C S.A.

Conditions

Parkinson Disease

Phase 1

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

CompletedNCT03094156

Bial - Portela C S.A.Parkinson Disease

Start: 2006-04-26End: 2006-07-11Updated: 2017-03-30

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

CompletedNCT03097211

Bial - Portela C S.A.Parkinson Disease

Start: 2006-07-17End: 2006-10-20Updated: 2017-03-31